Association of Methylene Blue Dosing With Hemodynamic Response for the Treatment of Vasoplegia

Hohlfelder, Benjamin; Douglas, Aaron; Wang, Lu; Wanek, Matthew; Bauer, Seth R.

doi:10.1053/j.jvca.2022.04.003

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methylene blue was clinically tested as a shock treatment in various clinical trials ( 11 , 12 ) evaluating different dosing strategies for methylene blue dosing regimens. They range from bolus administration regimens to bolus administration followed by continuous infusion, or continuous infusion only without additional bolus ( 13 ). To date, no studies have investigated the optimal dose strategy for methylene blue in critically ill patients with shock, mainly due to the complex pharmacological properties of methylene blue.…”

Section: Introductionmentioning

confidence: 99%

“…To date, no studies have investigated the optimal dose strategy for methylene blue in critically ill patients with shock, mainly due to the complex pharmacological properties of methylene blue. It has a large volume of distribution (up to 250 l) and a long half-life of up to 24 h ( 13 ), making the prediction of clinical effects and hemodynamic responses difficult.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methylene blue dosing strategies in critically ill adults with shock—A retrospective cohort study

Sari-Yavuz

Heck-Swain²,

Keller³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundShock increases mortality in the critically ill and the mainstay of therapy is the administration of vasopressor agents to achieve hemodynamic targets. In the past, studies have found that the NO-pathway antagonist methylene blue improves hemodynamics. However, the optimal dosing strategy remains elusive. Therefore, we investigated the hemodynamic and ICU outcome parameters of three different dosing strategies for methylene blue.MethodsWe performed a retrospective cohort study of patients in shock treated with methylene blue. Shock was defined as norepinephrine dose >0.1 μg/kg/min and serum lactate level >2 mmol/l at the start of methylene blue administration. Different demographic variables, ICU treatment, and outcome parameters were evaluated. To compare the differences in the administration of vasopressors or inotropes, the vasoactive inotropic score (VIS) was calculated at different time points after starting the administration of methylene blue. Response to methylene blue or mortality at 28 days were assessed.Results262 patients from July 2014 to October 2019 received methylene blue. 209 patients met the inclusion criteria. Three different dosing strategies were identified: bolus injection followed by continuous infusion (n = 111), bolus injection only (no continuous infusion; n = 59) or continuous infusion only (no bolus prior; n = 39). The groups did not differ in demographics, ICU scoring system, or comorbidities. In all groups, VIS decreased over time, indicating improved hemodynamics. Cardiogenic shock and higher doses of norepinephrine increased the chance of responding to methylene blue, while bolus only decreased the chance of responding to methylene blue treatment. 28-day mortality increased with higher SAPSII scores and higher serum lactate levels, while bolus injection followed by continuous infusion decreased 28-day mortality. No severe side effects were noted.ConclusionIn this cohort, methylene blue as a bolus injection followed by continuous infusion was associated with a reduced 28-day mortality in patients with shock. Prospective studies are needed to systematically evaluate the role of methylene blue in the treatment of shock.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Methylene blue dosing strategies in critically ill adults with shock—A retrospective cohort study

Sari-Yavuz

Heck-Swain²,

Keller³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Methylene blue was clinically tested as a shock treatment in several clinical trials [11,12] evaluating different dosing strategies for methylene blue dosing regimens. They range from bolus administration regimens to bolus administration followed by continuous infusion, or continuous infusion only without additional bolus [13]. To date, no studies have investigated the optimal dose strategy for methylene blue in critically ill patients with shock, mainly due to the complex pharmacological properties of methylene blue.…”

mentioning

confidence: 99%

“…To date, no studies have investigated the optimal dose strategy for methylene blue in critically ill patients with shock, mainly due to the complex pharmacological properties of methylene blue. It has a large volume of distribution (up to 250 l) and a long half-life of up to 24 hours [13], making the prediction of clinical effects and hemodynamic responses di cult.…”

mentioning

confidence: 99%

Methylene blue dosing strategies in critically ill adults with shock – a retrospective cohort study

Sari-Yavuz

Heck-Swain

Keller

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Shock increases mortality in the critically ill and the mainstay of therapy is the administration of vasopressor agents to achieve hemodynamic targets. In the past, studies have found that the NO-pathway antagonist methylene blue improves hemodynamics. However, the optimal dosing strategy remains elusive. Therefore, we investigated the hemodynamic and ICU outcome parameters of three different dosing strategies for methylene blue. Methods: We performed retrospective cohort study of patients in shock treated with methylene blue. Shock was defined as norepinephrine dose > 0.1 µg/kg/min and serum lactate level > 2 mmol/l at the start of methylene blue administration. Different demographic variables, ICU treatment, and outcome parameters were evaluated. To compare the differences in the administration of vasopressors or inotropes, the vasoactive inotropic score (VIS) was calculated at different time points after starting the administration of methylene blue. Response to methylene blue or mortality at 28 days were assessed. Results: 262 patients from July 2014 to October 2019 received methylene blue. 209 patients met the inclusion criteria. Three different dosing strategies were identified: bolus injection followed by continuous infusion (n=111), bolus injection only (no continuous infusion; n=59) or continuous infusion only (no bolus prior; n=39). The groups did not differ in demographics, ICU scoring system, or comorbidities. In all groups, VIS decreased over time, indicating improved hemodynamics. Cardiogenic shock and higher doses of norepinephrine increased the chance of responding to methylene blue, while bolus only decreased the chance of responding to methylene blue treatment. 28-day mortality increased with higher SAPSII scores and higher serum lactate levels, while bolus injection followed by continuous infusion decreased 28-day mortality. No severe side effects were notedConclusions: Methylene blue as a bolus injection followed by continuous infusion decreases 28-day mortality in patients with shock. Clinicians should consider the administration of methylene blue in patients with refractory shock, regardless of the cause.

show abstract

Optimal, Early Postoperative Management of Cardiac Transplant and Durable Left Ventricular Assist Recipients

2022

View full text Add to dashboard Cite

Association of Methylene Blue Dosing With Hemodynamic Response for the Treatment of Vasoplegia

Cited by 4 publications

References 22 publications

Methylene blue dosing strategies in critically ill adults with shock—A retrospective cohort study

Methylene blue dosing strategies in critically ill adults with shock—A retrospective cohort study

Methylene blue dosing strategies in critically ill adults with shock – a retrospective cohort study

Optimal, Early Postoperative Management of Cardiac Transplant and Durable Left Ventricular Assist Recipients

Contact Info

Product

Resources

About